PMID- 28693610 OWN - NLM STAT- MEDLINE DCOM- 20180410 LR - 20191210 IS - 1746-1596 (Electronic) IS - 1746-1596 (Linking) VI - 12 IP - 1 DP - 2017 Jul 10 TI - GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15. PG - 51 LID - 10.1186/s13000-017-0638-z [doi] LID - 51 AB - BACKGROUND: GATA-binding protein 3 (GATA3) has been identified as a sensitive marker for breast carcinoma but its sensitivity in primary genital extramammary Paget diseases (EMPDs) has not been well studied. METHODS: Here we investigated immunohistochemical expression of GATA3 in 72 primary genital EMPDs (35 from female, 37 from male; 45 with intraepithelial disease only, 26 with both intraepithelial disease and invasive adenocarcinoma including 14 also metastasis, 1 with metastatic adenocarcinoma only for study). We also compared GATA3 to gross cystic disease fluid protein 15 (GCDFP15) for their sensitivity. RESULTS: Positive GATA3 staining was seen in all 71 (100%) intraepithelial diseases, 25/26 (96%; female 10/10, male 15/16) invasive adenocarcinomas and 14/15 (93%; female 3/3, male 11/12) metastatic adenocarcinomas, respectively. Positive GCDFP15 staining was seen in 46/71 (65%; female 28/34 or 82%, male 18/37 or 49%) intraepithelial diseases, 20/26 (77%; female 9/10, male 11/16) invasive adenocarcinomas, and 12/15 (80%; female 2/3, male 10/12) metastatic adenocarcinomas, respectively (GATA3 versus GCDFP15: p < 0.01 for both intraepithelial disease and invasive adenocarcinoma, p = 0.28 for metastatic adenocarcinoma). In positive-stained cases, GATA3 stained more tumor cells than GCDFP15 (79% versus 25% for intraepithelial disease, 71% vs 34% for invasive adenocarcinoma, 73% vs 50% for metastatic adenocarcinoma, p < 0.01 for all 3 components). CONCLUSIONS: Our findings indicate that GATA3 is a very sensitive marker for primary genital EMPDs and is more sensitive than GCDFP15. FAU - Zhao, Ming AU - Zhao M AD - Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, China. FAU - Zhou, Lixin AU - Zhou L AD - Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital (Beijing Cancer Hospital), Beijing, China. FAU - Sun, Li AU - Sun L AD - Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital (Beijing Cancer Hospital), Beijing, China. FAU - Song, Yan AU - Song Y AD - Department of Pathology, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China. FAU - Guo, Yunquan AU - Guo Y AD - Department of Pathology, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, China. FAU - Zhang, Xun AU - Zhang X AD - Department of Pathology, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhao, Feng AU - Zhao F AD - Department of Pathology, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, China. FAU - Wang, Peng AU - Wang P AD - Department of Pathology, Beijing Ditan Hospital, Beijing, China. FAU - Yue, Junqiu AU - Yue J AD - Department of Pathology, Hubei Cancer Hospital, Wuhan, China. FAU - Niu, Dongfeng AU - Niu D AD - Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital (Beijing Cancer Hospital), Beijing, China. FAU - Li, Zhongwu AU - Li Z AD - Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital (Beijing Cancer Hospital), Beijing, China. FAU - Huang, Xiaozheng AU - Huang X AD - Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital (Beijing Cancer Hospital), Beijing, China. FAU - Kang, Qiang AU - Kang Q AD - Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital (Beijing Cancer Hospital), Beijing, China. FAU - Jia, Lin AU - Jia L AD - Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital (Beijing Cancer Hospital), Beijing, China. FAU - Lai, Jinping AU - Lai J AD - Department of Pathology, Saint Louis University School of Medicine, Saint Louis, MO, USA. FAU - Cao, Dengfeng AU - Cao D AD - Department of Pathology and Immunology, Washington University School of Medicine, 660 S South Euclid Avenue Campus Box 8118, Saint Louis, MO, 63110, USA. dcao@path.wustl.edu. LA - eng PT - Comparative Study PT - Journal Article DEP - 20170710 PL - England TA - Diagn Pathol JT - Diagnostic pathology JID - 101251558 RN - 0 (Biomarkers, Tumor) RN - 0 (Carrier Proteins) RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) RN - 0 (Glycoproteins) RN - 0 (Membrane Transport Proteins) RN - 0 (PIP protein, human) SB - IM MH - Adenocarcinoma/metabolism MH - Biomarkers, Tumor/metabolism MH - Breast Neoplasms/metabolism/pathology MH - Carrier Proteins/*metabolism MH - Female MH - GATA3 Transcription Factor/*metabolism MH - Genital Diseases, Female/*metabolism MH - Genital Diseases, Male/*metabolism MH - Glycoproteins/*metabolism MH - Humans MH - Immunohistochemistry/methods MH - Male MH - Membrane Transport Proteins MH - Paget Disease, Extramammary/diagnosis/*pathology PMC - PMC5504764 OTO - NOTNLM OT - Extramammary Paget disease OT - GATA3 OT - GCDFP15 OT - Immunohistochemical marker COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was approved by the ethics committees of Zhejiang Provincial's People's Hospital, Beijing Cancer Hospital, Beijing Ditan Hospital, Xinjiang Cancer Hospital, and Institutional Review Board of Washington University in Saint Louis (IRB 201601008, 201,601,009). CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2017/07/12 06:00 MHDA- 2018/04/11 06:00 PMCR- 2017/07/10 CRDT- 2017/07/12 06:00 PHST- 2017/02/21 00:00 [received] PHST- 2017/06/26 00:00 [accepted] PHST- 2017/07/12 06:00 [entrez] PHST- 2017/07/12 06:00 [pubmed] PHST- 2018/04/11 06:00 [medline] PHST- 2017/07/10 00:00 [pmc-release] AID - 10.1186/s13000-017-0638-z [pii] AID - 638 [pii] AID - 10.1186/s13000-017-0638-z [doi] PST - epublish SO - Diagn Pathol. 2017 Jul 10;12(1):51. doi: 10.1186/s13000-017-0638-z.